We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Parents, patients and physicians who decide to launch a pharmaceutical course of treatment for attention-deficit/hyperactivity disorder must wade through a large pool of offerings -- twice as many as available in Europe -- with little scientific data to guide them, market analysts say.
Aspreva Pharmaceuticals Corporation , an emerging pharmaceutical company focused on increasing the pool of evidence-based medicines for patients with less common diseases, today announced preliminary revenues of approximately US$62 million for the first quarter of 2006.
Neuroscience Therapy Corp. announced today that it now holds the exclusive distribution rights in Central and South America for its leading product P-Stim, a patent protected medical device used to treat a variety of acute and chronic pain conditions.
Genetically modified yeast could help overcome a global shortage of the most effective drug for malaria -a particular health concern in Africa -- according to research conducted at the University of California at Berkeley and published in the journal Nature.
A vaccine against human papilloma virus (HPV), the virus that causes most cases of cervical cancer, appears to protect women for more than four years, according to research published in the British journal The Lancet.
GlaxoSmithKline Pharma (GSK), the India-based subsidiary of the British drugmaker, plans to vastly expand its vaccines business in India, the company has announced. GSK is currently conducting clinical trials in India on vaccines against rotavirus, cervical cancer, hepatitis B and polio.
Raisio is gearing up to launch its Benecol brand of plant-stanol containing foods in Russia -- a challenging market where obesity and cardiovascular disease levels are high but awareness of the dangers of high cholesterol is low.
Neuromed Pharmaceuticals, a biopharmaceutical company developing next-generation chronic pain drugs, announced today that it has been named to FierceBiotech's annual Fierce 15 list of top biotech companies to watch.
Biovail Corporation announced today that Wellbutrin XL, the first once-daily extended-release formulation of bupropion hydrochloride approved for the Canadian market for the treatment of depression in adults, has been officially launched and is commercially available.